CN Patent

CN117430647A — 一种瑞加诺生的制备方法

Assigned to Kamp Pharmaceuticals Co Ltd · Expires 2024-01-23 · 2y expired

What this patent protects

本发明提供了一种瑞加诺生的制备方法，该方法以2‑氯腺嘌呤核苷为起始物料，先与水合肼反应，再与2‑甲酰基‑3‑氧代丙酸乙酯缩合成吡唑环，经甲胺氨解制备获得瑞加诺生。本发明方法操作简便、反应条件温和、收率高、成本低、对环境友好、适合工业化大规模生产瑞加诺生。

USPTO Abstract

本发明提供了一种瑞加诺生的制备方法，该方法以2‑氯腺嘌呤核苷为起始物料，先与水合肼反应，再与2‑甲酰基‑3‑氧代丙酸乙酯缩合成吡唑环，经甲胺氨解制备获得瑞加诺生。本发明方法操作简便、反应条件温和、收率高、成本低、对环境友好、适合工业化大规模生产瑞加诺生。

Drugs covered by this patent

Patent Metadata

Patent number
CN117430647A
Jurisdiction
CN
Classification
—
Expires
2024-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Kamp Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.